Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 1

Status

Unknown 5Completed 5Recruiting 4Terminated 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 118Neoplasms 14Neoplasm Metastasis 14Multiple Endocrine Neoplasia Type 1 5Advanced Breast Cancer 5Prostatic Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Breast Cancer Metastatic 3Recurrence 2Lymphoma 2Lung Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Small Cell Lung Carcinoma 1Sex Cord-Gonadal Stromal Tumors 1Sarcoma, Endometrial Stromal 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Patient Acceptance of Health Care 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplastic Cells, Circulating 1Neoplasms by Site 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lethal Congenital Contracture Syndrome 2 1Hyperglycemia 1

Interventions

Fulvestrant 5Anastrozole 4Letrozole 3Docetaxel 2Dasatinib 2vandetanib 1sonidegib 1ribociclib 1pembrolizumab 1palbociclib 1olaparib 1irinotecan sucrosofate 1exemestane 1cediranib 1XMT-1522 1Vorinostat 1Tablets 1Ritonavir 1Population Groups 1Paclitaxel 1Moxifloxacin 1Itraconazole 1Histone Deacetylase Inhibitors 1Gemcitabine 1FCN-437c 1Everolimus 1Electroporation 1Cryosurgery 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Advanced Breast Cancer × Fulvestrant × Clear all
NCT00454805 2016-08-03

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

AstraZeneca

Phase 2 Completed
75 enrolled 11 charts
Breast

Advanced Breast Cancer

NCT00754325 2016-05-26

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Bristol-Myers Squibb

Phase 2 Completed
100 enrolled 13 charts
Breast

Advanced Breast Cancer

NCT00327769 2011-01-25

Faslodex Advanced Breast Cancer Local Chinese Study

AstraZeneca

Phase 3 Completed
234 enrolled
Breast

Advanced Breast Cancer

NCT00328120 2010-11-17

Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

AstraZeneca

Phase 1 Completed
20 enrolled
Breast

Advanced Breast Cancer

NCT00635713 2009-04-10

Second Line Breast Cancer Trial

AstraZeneca

Phase 3 Completed
588 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡